These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1116149)

  • 1. The activity of regional nodes in the evolution of immune responses to allogeneic and isogeneic tumors.
    Barna B; Deodhar SD
    Cancer Res; 1975 Apr; 35(4):920-6. PubMed ID: 1116149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological activity of regional lymph nodes in tumor-bearing mice.
    Barna BP; Deodhar SD
    Cancer Res; 1979 Jul; 39(7 Pt 1):2711-7. PubMed ID: 312691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of regional and distant lymph nodes in rejection of feline sarcoma virus-induced tumors in sheep.
    Thellen GH; Pedersen NC; Higgins J
    J Natl Cancer Inst; 1979 Aug; 63(2):389-400. PubMed ID: 222930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the immunosuppressive drug niridazole in isogeneic and allogeneic mouse tumor systems in vivo.
    Deodhar SD; Lee VW; Chiang T; Mahmoud AF; Watten KS
    Cancer Res; 1976 Sep; 36(9 pt.1):3147-50. PubMed ID: 975080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. IV. Lymph node immunoreactivity and cell-mediated cytotoxicity.
    Laatikainen A; Syrjänen K; Mäntyjärvi R; Tosi P
    Neoplasma; 1987; 34(4):431-9. PubMed ID: 3116439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage migration inhibition-activity after implantation of methylcholanthrene-induced sarcoma, Ehrlich ascites cancer or mouse ascites hepatoma-134 cancer cells in mice.
    Yumura M
    Acta Med Okayama; 1976 Feb; 30(1):37-48. PubMed ID: 184687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-lapse changes in the concomitant immunity of lymphocytes from different sites of mice isografted with methylcholanthrene-induced tumor.
    Orita K; Ohnishi N; Matuso Y; Konaga E; Kokumai Y
    Acta Med Okayama; 1975 Apr; 29(2):85-91. PubMed ID: 126005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response of mice to sarcoma I allograft studied by adoptive transfers of spleen, thymus, and lymph node cells to secondary recipients.
    Vidrnová M; Nouza K; Panajotovová V
    Neoplasma; 1985; 32(4):451-61. PubMed ID: 4047256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts.
    Fujimoto S; Greene MI; Sehon AH
    J Immunol; 1976 Mar; 116(3):800-6. PubMed ID: 1254955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.
    Fuji N; Ueda Y; Fujiwara H; Toh T; Yoshimura T; Yamagishi H
    Clin Cancer Res; 2000 Aug; 6(8):3380-7. PubMed ID: 10955826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.
    Kurzawa H; Wysocka M; Aruga E; Chang AE; Trinchieri G; Lee WM
    Cancer Res; 1998 Feb; 58(3):491-9. PubMed ID: 9458095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors.
    Basombrío MA; Prehn RT
    Cancer Res; 1972 Nov; 32(11):2545-50. PubMed ID: 5082598
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s).
    Lamon EW; Skurzak HM; Andersson B; Whitten HD; Klein E
    J Immunol; 1975 Apr; 114(4):1171-6. PubMed ID: 1117138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
    Marsili MA; Walker MC; Phillips-Quagliata JM
    Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients.
    Russell PS; Chase CM; Burton RC
    J Immunol; 1983 Feb; 130(2):951-7. PubMed ID: 6336775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of blocking by hyperimmune serum of lymphocyte-mediated cytolysis of allogeneic tumor cells.
    Todd RF; Stulting RD; Berke G
    Cancer Res; 1973 Dec; 33(12):3203-8. PubMed ID: 4760536
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
    Aruga A; Aruga E; Chang AE
    Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.